Table 2.
Summary of susceptibility assays
| MIC against E. coli strains [μM] | Hemolysis of mouse red blood cells [%] | Toxicity IC50 [μM] | TI | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peptide | TOP10 | ATCC 25922 | BW 25113 | BW 25113 ∆sbmA | Clinical isolates (MIC50) | 1xMIC | 4xMIC | HeLa | HEK 293 | Toxicity/MIC |
| Bac71-23 | 4.6 | 2.8 | 7.4 | 52.1 | 7.5 | 2.1% | 6.4% | 1460 | 1970 | 195 |
| Bac7PS | 2.1 | 2.6 | 3.6 | 14.4 | 2.9 | 3.1% | 3.8% | 521 | 755 | 180 |
MIC values are averaged (n>3) and performed under CSLI standards in the MHB II medium. Hemolysis assays and toxicity measurements were performed in triplicates. The therapeutic index (TI) is calculated by dividing the IC50 values measured with HeLa cells by the MIC50 obtained from clinical isolates (see Fig. 4a)